LIR Life Sciences Corp. (CSE:SKNY)

LIR Life Sciences Ratios and Metrics

Market cap in millions CAD. Fiscal year is May - April.

Total Valuation

Fiscal Year	Current	FY 2026	FY 2025	FY 2024
Period Ending	Sep 17, 2026	Apr 30, 2026	Apr 30, 2025	Apr 30, 2024
Market Capitalization	5	15	-	-
Market Cap Growth	-	-	-	-
Enterprise Value	5	14	-	-
Last Close Price	0.18	0.55	-	-

Price Ratios

Fiscal Year	Current	FY 2026	FY 2025	FY 2024
Period Ending	Sep 17, 2026	Apr 30, 2026	Apr 30, 2025	Apr 30, 2024
PB Ratio	7.86	23.35	-	-
P/TBV Ratio	7.86	23.35	-	-

Financial Efficiency

Fiscal Year	Current	FY 2026	FY 2025	FY 2024
Period Ending	Sep 17, 2026	Apr 30, 2026	Apr 30, 2025	Apr 30, 2024
Debt / Equity Ratio	-	-	-	-7.06
Net Debt / Equity Ratio	-0.91	-0.91	1.47	0.00
Net Debt / EBITDA Ratio	0.17	0.17	-	-
Quick Ratio	3.68	3.68	0.60	0.88
Current Ratio	4.64	4.64	0.60	0.88
Return on Equity (ROE)	-1357.83%	-1357.83%	-	-
Return on Assets (ROA)	-447.87%	-447.87%	-162.64%	-
Return on Capital Employed (ROCE)	-522.80%	-522.80%	516.10%	300.00%

Yields

Fiscal Year	Current	FY 2026	FY 2025	FY 2024
Period Ending	Sep 17, 2026	Apr 30, 2026	Apr 30, 2025	Apr 30, 2024
Earnings Yield	-75.55%	-25.44%	-	-
Buyback Yield / Dilution	-331.53%	-331.53%	-41648.94%	-

Data Source: S&P Global Market Intelligence Last updated: Aug 29, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 17, 2026

Data Sources Report a data error